Literature DB >> 11013032

Long-term fate of the aneurysmal sac after endoluminal exclusion of abdominal aortic aneurysms.

R Y Rhee1, M K Eskandari, A B Zajko, M S Makaroun.   

Abstract

PURPOSE: Shrinkage of an abdominal aortic aneurysm (AAA) is the hallmark of successful endoluminal treatment. Our goal was to prospectively assess the midterm to long-term shrinkage of the AAA sac after endovascular repair.
METHODS: A total of 123 patients with AAA underwent endoluminal treatment with the Ancure device at our institution between February 1996 and February 2000. At least a 1-year follow-up was available for 70 of the 123 patients. AAA sac size, presence of endoleaks, calcifications, and outcome data were collected on these patients at 6, 12, 24, and 36 months after repair and compared with the preoperative AAA size and characteristics. All endoleaks found at the 6-month follow-up visit were treated aggressively with embolotherapy. An AAA sac regression of 0.5 cm or more was considered the minimum measurable decrease. Regression of the sac diameter to 3.5 cm or less was considered a complete collapse of the sac.
RESULTS: Successful endoluminal repair was accomplished in 119 of 123 patients. The mortality rate was 0.8% (1/123). There was a steady decrease in AAA sac size from baseline (5.56 +/- 0.1 cm), to 6 months (5.0 +/- 0.14 cm, P =.0006), to 12 months (4.65 +/- 0.13 cm, P =.04), and to 24 months (4.26 +/- 0.16 cm, P =.03). At 24 months, 74% (29/39) had a decrease in sac size of 0.5 cm or more, with 28% (11/39) complete collapse. Patients with initial endoleaks had the same likelihood of regression of sac size (> or = 0.5 cm) when compared with the group of patients with no endoleaks at the 24-month evaluation (64% vs 76%, P =.09).
CONCLUSION: Endoluminal AAA repair resulted in a significant reduction in sac size that continues up to 2 years. Significant shrinkage occurs as early as 6 months after placement. The initial presence of endoleaks does not predict the lack of sac regression.

Entities:  

Mesh:

Year:  2000        PMID: 11013032     DOI: 10.1067/mva.2000.110172

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  7 in total

1.  Increasing incidence of midterm and long-term complications after endovascular graft repair of abdominal aortic aneurysms: a note of caution based on a 9-year experience.

Authors:  T Ohki; F J Veith; P Shaw; E Lipsitz; W D Suggs; R A Wain; M Bade; M Mehta; N Cayne; J Cynamon; J Valldares; J McKay
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

2.  Factors affecting the regression of surgically replaced abdominal aortic aneurysms.

Authors:  Masahiro Matsushita; Teruo Ikezawa
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

3.  Predictors and Consequences of Sac Shrinkage after Endovascular Infrarenal Aortic Aneurysm Repair.

Authors:  Sébastien Michel Vedani; Séverine Petitprez; Eva Weinz; Jean-Marc Corpataux; Sébastien Déglise; Céline Deslarzes-Dubuis; Elisabeth Côté; Jean-Baptiste Ricco; François Saucy
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

Review 4.  Endotension: twenty years of a controversial term.

Authors:  Álvaro Torres-Blanco; Manuel Miralles-Hernández
Journal:  CVIR Endovasc       Date:  2021-06-05

5.  Early sac shrinkage predicts a low risk of late complications after endovascular aortic aneurysm repair.

Authors:  F Bastos Gonçalves; H Baderkhan; H J M Verhagen; A Wanhainen; M Björck; R J Stolker; S E Hoeks; K Mani
Journal:  Br J Surg       Date:  2014-04-22       Impact factor: 6.939

6.  Late open conversion after endovascular repair of abdominal aneurysm failure: Better and easier option than complex endovascular treatment.

Authors:  Stefano Bonardelli; Franco Nodari; Maurizio De Lucia; Emanuele Botteri; Alice Benenati; Edoardo Cervi
Journal:  JRSM Cardiovasc Dis       Date:  2018-03-14

7.  Endovascular repair of abdominal aortic aneurysm: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2002-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.